TGFB1 and prostate carcinoma: matrix metalloproteinases: MMP-1, MMP-2, MMP-13, receptor activators of nuclear factor κ-B: RANK, receptor activators of nuclear factor κ-B ligand: RANKL, and tissue inhibitor of metalloproteinase, TIMP-2), TGFβ was found to be present in highest amounts in blood platelets taken from animals with a prostate cancer model (inoculation with LNCaP-C4-2 cells); it was described as a protein sequestered and transportedby blood platelets from the primary tumour to the premetastatic niche.